Dr Herbst on Adjuvant Osimertinib in EGFR-mutant NSCLC : com

Roy S. Herbst, MD, PhD, discusses findings from the overall survival analysis of the phase 3 ADAURA trial of adjuvant osimertinib in patients with stage IB to IIIA resected non–small cell lung cancer harboring EGFR mutations.

Related Keywords

Roys Herbst , , Yale School Of Medicine , Yale Cancer Center , Ensign Professor , Medical Oncology , Thoracic Cancers , Smilow Cancer Hospital , Yale School , D , Phd , Adaura Trial , Nct02511106 , Padjuvant Osimertinib , Patients With Stage Ib To Iiia Resected Non Small Cell Lung Cancer Harboring Egfr Mutations ,